The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 27, 2018

Filed:

Jul. 03, 2017
Applicant:

Development Center for Biotechnology, New Taipei, TW;

Inventors:

Jiann-Shiun Lai, New Taipei, TW;

Li-Shuang Ai, New Taipei, TW;

Yan-Da Lai, New Taipei, TW;

Yen-Yu Wu, New Taipei, TW;

Yi-San Tsai, New Taipei, TW;

Yi-Jiue Tsai, New Taipei, TW;

Juo-Yu Huang, New Taipei, TW;

Cheng-Chou Yu, New Taipei, TW;

Chuan-Lung Hsu, New Taipei, TW;

Chien-Tsun Kuan, New Taipei, TW;

Szu-Liang Lai, New Taipei, TW;

Li-Ya Wang, New Taipei, TW;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/74 (2006.01); A61K 51/10 (2006.01); A61K 31/4439 (2006.01); C07K 14/71 (2006.01); C07K 16/00 (2006.01); A61K 47/68 (2017.01); A61K 47/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 31/4439 (2013.01); A61K 47/48561 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); A61K 51/1096 (2013.01); C07K 14/71 (2013.01); C07K 16/005 (2013.01); C07K 16/2818 (2013.01); C07K 16/30 (2013.01); G01N 33/74 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/71 (2013.01);
Abstract

The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.


Find Patent Forward Citations

Loading…